Currently approved antiviral drugs target only 10 of the 220 known viruses that are responsible for causing serious infection in humans, which has necessitated the development of novel antiviral therapeutics
Roots Analysis has announced the addition of “Antiviral Drugs Market, 2022 – 2035” report to its list of offerings.
The recent COVID-19 pandemic has exposed the lack of effective antiviral therapeutics that can be used for the treatment of re-emerging or emerging viral diseases and has highlighted the need for the development of safe and effective novel antiviral therapeutics. With around 80 approved antiviral drugs, a promising development pipeline, and encouraging clinical trial results, the antiviral drugs market is likely to witness notable growth in the mid to long-term.
To order this 190+ page report, which features 85+ figures and 110+ tables, please visit this link
Around 80 antiviral drugs have been approved, till date, targeting several infectious diseases
Around 45% of the abovementioned therapeutics have been approved post 2011. Majority of the approved antiviral drugs (~75%) are delivered via oral route of administration. Further, 50% of the drugs are approved for targeting HIV infection, followed by those approved for hepatitis (12%).
Around 430 antiviral drugs are currently being evaluated in clinical trials
Majority (~70%) of the aforementioned therapies are being evaluated in early stages of development (phase I, phase I/II and phase II). Further, around 45% of the drugs are being investigated as solid dosage forms (tablets and capsules).
Partnership activity has grown at an annualized rate of nearly 140%, between 2019-2022
Maximum number of partnerships were established in 2020 (104) and 2021 (82), which indicate the recent surge in the partnership activity in this domain. Majority of these (~20%) were clinical trial agreements. Further, most of the intercontinental, as well as intracontinental deals have been inked by the players based in North America.
Around USD 5.5 billion has been invested by both private and public investors, since 2019
Specifically, in 2021, industry players raised over USD 4.7 billion. More than 30% of the organizations engaged in this domain primarily raised funding through venture capital rounds. Further, around 55% of the total funding instances were reported by players headquartered in the US.
North America and Europe are anticipated to capture larger share (~70%) of the market by 2035
In addition, the market in Asia-Pacific is likely to grow at a relatively faster pace (8.4%) in the long term. Further, in 2035, major share (60%) of the revenues is likely to be generated from the sales of reverse transcriptase inhibitors and protease inhibitors. In terms of target indications, antiviral drugs targeting HIV infections are anticipated to capture the highest share (44%); this trend is unlikely to change in the foreseen future.
To request a sample copy / brochure of this report, please visit this link
The financial opportunity within the antiviral drugs market has been analyzed across the following segments:
The research also includes detailed profiles of key players (listed below) featuring a brief overview of the company, details related to antiviral drugs portfolio, recent developments, and an informed future outlook.
For additional details, please visit https://www.rootsanalysis.com/reports/antiviral-drugs-market.html or email sales@rootsanalysis.com
You may also be interested in the following titles:
Contact:
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Gaurav.chaudhary@rootsanalysis.com
MEDIA CITATIONS
We are your partners with no equity
We fit in your budget
We love what we do
Chance to prove ourselves
Best in class quality of work
Most trusted consulting partner in the industry
SUBSCRIBE TO INDUSTRY UPDATES
.png)
